Medicamen Biotech Limited has announced that its board of directors will meet on Wednesday, May 27, 2026. The meeting will be held at the company's registered office in New Delhi to discuss and approve key agenda items for the financial year ending March 31, 2026.

Agenda for the Board Meeting

The primary focus of the meeting is to consider and approve the audited financial results of the company for the quarter and year ended March 31, 2026. These results will include both standalone and consolidated figures. The board will also deliberate on the recommendation of a final dividend on equity shares for the financial year 2025-26, subject to approval.

Auditor Appointments

In addition to financial results, the board will consider the appointment of statutory auditors for the upcoming financial year. The agenda includes the appointment of M/s SPB & Co, Cost Accountants, as the Cost Auditor for the financial year 2026-27. Furthermore, the board will consider appointing M/s Cheena & Associates as the Internal Auditor for the same period.

Trading Window Closure

In compliance with the SEBI (Prevention of Insider Trading) Regulations, 2015, the trading window for dealing in the company's securities has been closed since April 1, 2026. The window will remain closed until 48 hours after the financial results are declared to the stock exchanges.

Medicamen biotech Limited has filed its quarterly compliance certificate with stock exchanges, fulfilling regulatory requirements under SEBI (Depositories and Participants) Regulations, 2018. The pharmaceutical company submitted the mandatory documentation for the quarter ended March 31, 2026, confirming compliance with securities dematerialization procedures.

Regulatory Compliance Submission

The company submitted its certificate under Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018, to both BSE Limited and National Stock Exchange of India Limited on April 15, 2026. Company Secretary Parul Choudhary signed the compliance certificate, which covers securities dematerialization and rematerialization activities during Q4FY26.

Compliance Confirmations

The company provided specific certifications regarding its securities handling procedures during the quarter. The compliance certificate confirms that all securities comprised in the dematerialization certificates have been properly listed on stock exchanges where the company's earlier issued securities were already listed.

Additionally, the company certified that all physical certificates received for dematerialization were mutilated and cancelled after due verification. The depository's name was substituted in the company's records as the registered owner within the mandatory 30-day timeline from receipt.

Registrar Confirmation

MUFG Intime India Private Limited, formerly Link Intime India Private Limited, serves as the company's registrar and share transfer agent. The registrar provided independent confirmation on April 14, 2026, validating the company's compliance with dematerialization procedures.

The registrar confirmed that securities received from depository participants during Q4FY26 were processed according to regulatory requirements, with proper verification and record-keeping procedures followed throughout the quarter.